Woman, 21, develops deadly blood complication after taking Mounjaro > 자유게시판

본문 바로가기


자유게시판

Woman, 21, develops deadly blood complication after taking Mounjaro

페이지 정보

작성자 Holly 작성일24-04-20 19:18 조회20회 댓글0건

본문

A 21-year-old woman developed lethal toxic blood after taking a popular weight loss drug for just three weeks. 

The unnamed patient, who had been injecting a medicine in the same class as Ozempic, was admitted to the hospital after two days of abdominal pain, vomiting, and diarrhea.  

Blood tests revealed that she was suffering a potentially fatal condition called ketoacidosis - which happens when fat-melting proteins called ketones build up in the blood.

In small, short-lived doses, ketones are relatively harmless, and can speed up weight loss. But in large quantities, they cause the blood to become too acidic, causing catastrophic heart problems. 

The patient, whose case was documented in the European Journal of Case Reports in Internal Medicine, Glucoslim Erfahrungsbericht was found to have 26 times the normal level of ketones in her blood. 











An unnamed patient in Kuwait went into ketoacidosis after taking tirzepatide, the active ingredient in blockbuster weight loss drugs Mounjaro and Zepbound





The cases have been recorded in an FDA monitoring system used to track the safety of medicines used in the US, called FAERS. They are shown above in a graphic







Three weeks earlier, she started taking tirzepatide, the active ingredient in blockbuster weight loss drugs Mounjaro and Zepbound, once a week. She had lost about 11 pounds. 

The complication is one in a long line of side effects linked to GLP-1 agonists like Ozempic and Mounjaro, which have also been tied to over 100 US deaths. 

Normally, the body breaks down glucose, or sugar, in food and converts it into energy. 

But if the body isn't getting enough, it breaks down fat stores as a backup. This chemical reaction produces ketones as a by-product.

This could be more likely in patients on GLP-1 agonists like Ozempic or Mounjaro because the medications suppress appetite, which means patients are not getting much energy from food.

Ketoacidosis is normally seen in diabetic patients, as their bodies cannot produce enough insulin - which helps convert food into energy - leaving fat to be broken down instead. 

댓글목록

등록된 댓글이 없습니다.


회사소개 | 개인정보취급방침 |

상호 : (주)다중지능연구소 | 대표이사 : 김범수 | 사업자등록번호 : 106-86-3186 | 주소 : 서울시 마포구 독막로 19길, 15 BR엘리텔 B동 201호 (121-828)
대표전화 : 02-704-6615 | 팩스 : 02-704-6693 | 이메일 : [email protected] Copyright © (주)다중지능연구소 All rights reserved.